Clinical trials: Nephrosis, Lipoid
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Healthy Volunteers
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
The goal of this research study is to learn more about the pancreas. The investigators want to use Magnetic Resonance Cholangiopancreatography (MRCP) to learn more about the size of a normal pancreas.
- Trial name
- NCT02869893
- Testing
- Secretin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Nephrosis, Focal Lipoid Glomerulosclerosis
Steroid Treatment for Kidney Disease
Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine.
- Trial name
- NCT00065611
- Testing
- Oral dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT02592798
- Testing
- Abatacept, Normal Saline, D5W
- Where
- 27 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Treatment Resistant Nephrotic Syndrome
Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR)
This study will examine the safety and effectiveness of ACTHAR Gel, when used to treat 15 patients diagnosed with "treatment resistant nephrotic syndrome." Nephrotic syndrome is a group of symptoms that includes low levels of…
- Trial name
- NCT01129284
- Testing
- ACTHAR gel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Columbia University
Idiopathic Nephrotic Syndrome
UrApp for Childhood Nephrotic Syndrome Management (Incident Cohort)
Idiopathic nephrotic syndrome is one of the most common chronic kidney diseases in children. Patients suffer from frequent disease relapses and complications.
- Trial name
- NCT04075656
- Testing
- Standard of Care, UrApp
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Emory University
Minimal Change Disease
Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease
The purpose of this study is to compare the effectiveness of tacrolimus (prograf) versus prednisolone for the treatment of nephrotic syndrome secondary to minimal change disease.
- Trial name
- MinTAC (NCT00982072)
- Testing
- tacrolimus, prednisolone
- Where
- United Kingdom
- Volunteers
- 52 people
- Sponsor
- Imperial College Healthcare NHS Trust